Cannasouth Limited (NZX:CBD), New Zealand’s first and largest listed medicinal cannabis company, is pleased to provide this trading update as the Group commences sales of its own-manufactured CBD oral solutions and dried cannabis flower products.
Group Revenues:
Oct-23 $26,000
Nov-23 $201,000
Dec-23 $243,000
Commercial sales of these products commenced in November 2023 following a lengthy verified process by the Medicinal Cannabis Agency. We are confident with the launch of our new products and expect ongoing revenue growth as clinics and prescribers obtain access to our product range either direct, or via wholesalers.
-ENDS-
For further information visit www.cannasouth.co.nz or contact:
Mark Lucas CEO / Executive Director
Email: [email protected]
Mobile: 021 484 649
Colin Foster
CFO / Company Secretary
Email: [email protected]
Mobile: 027 577 1498
The S&P/NZX 50 Index closed at the day’s low of 12,349.47, down 46.79 points or 0.38%.
Forsyth Barr says a premium valuation is now warranted.
The only worst performer is the Norwegian krone.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details